Well, things are heating up really quickly lately!
Just 1 day and I was able to ring the register on ADAP over $13! Gains are coming quickly – which I always love!
Option Rocket members also enjoyed a nice 50% win at the open on CYBR. Congrats to those in there!
I also added to some gains in the Biotech Nucleus Room by trading huge winnerACHV today.
All around, money is rolling in!
—– Related —–
FREE DOWNLOAD
Kyle Dennis FREE EBOOK “The $2.9 Million Biotech Trader Playbook”
This book has helped thousands of other traders learn the basics of biotech, and how to easily spot winning trades.
Whether you are new trader or a 30-year veteran, this book will help you find stocks that are primed to make parabolic moves. These strategies are Kyle’s secret weapons that have help him net over $3 Million in profits…and they are all yours for free.
This is normally $97.00, but it’s yours FREE!
I still hold ACHN and it is performing well. I also picked up short term (1-3 day swing trades) in ACRX and CVM. I like to “strike when the iron is hot” and be more active when the markets are easy.
So, that is why I’m including some of these shorter term trades right now.
I hope you are enjoying them and making money!
I’ll be refining the watch list this weekend and adjusting our “zones”, so stay tuned for that as well!
Reminder: Charts are updated every Sunday evening for the next week!
New Catalyst Swing Names (1-4 week holds) that I am watching
Adaptimmune Therapeutics (ADAP)
Catalyst Dates: Late breaking Phase 1 data due out October 19-23
Buy Zone: $11.50 to $12.00
Profit Zone: $13.00 or higher
Stop Zone: $11.25 or below
Karyopharm Therapeutics (KPTI)
Catalyst Dates: Late breaking data due out October 19-23
Buy Zone: $16.50 to $17.50
Profit Zone: $18.00 or higher
Stop Zone: $16.05 or below
Catalyst Swing Names (1-4 week holds) that I am watching
Axsome Therapeutics (AXSM)
Catalyst Dates: Phase 2 data for major depressive disorder due in the fourth quarter. Phase 3 data due out in the second half of 2018. Another Phase 2 interim data due out in the 4th quarter. R&D day October 18th.
Buy Zone: $3.10 to $3.40
Profit Zone: $4.00 or higher
Stop Zone: $2.95 or below
Immunogen (IMGN)
Catalyst Dates: Phase 1b/2 data due out October 19-23
Buy Zone: $9.00 to $9.35
Profit Zone: $10.30 or higher
Stop Zone: $8.70 or below
Clovis Oncology (CLVS)
Catalyst Dates: Phase 2 data due October 21
Buy Zone: $31.50 to $32.50
Profit Zone: $35.00 or higher
Stop Zone: $30.00 or below
Catalyst Biosciences (CBIO)
Catalyst Dates: Updated data due out late 3Q or early 4Q
Buy Zone: $10.00 to $10.30
Profit Zone: $11.50 or higher
Stop Zone: $9.50 or below
Catalyst Pharmaceuticals (CPRX)
Catalyst Dates: FDA approval date of November 28th
Buy Zone: $2.90 to $3.20
Profit Zone: $3.80 or higher
Stop Zone: $2.70 or below
Sellas Life Corp (SLS)
Catalyst Dates: Phase 2 interim data due out October 19-23
Buy Zone: $1.05 to $1.15
Profit Zone: $1.50 or higher
Stop Zone: $.95 or below
Epizyme (EPZM)
Catalyst Dates: Phase 2 data update October 19-23.
Buy Zone: $10.00 to $10.30
Profit Zone: $11.50 or higher
Stop Zone: $9.50 or below
Halozyme (HALO)
Catalyst Dates: Present updated pancreatic cancer data October 19-23
Buy Zone: $17.25 to $17.75
Profit Zone: $18.50 or higher
Stop Zone: $16.80 or below
EyePoint Pharmaceuticals (EYPT)
Catalyst Dates: FDA approval date of November 5th
Buy Zone: $2.40 to $2.60
Profit Zone: $3.00 or higher
Stop Zone: $2.10 or below
AVEO Pharmaceuticals (AVEO)
Catalyst Dates: Updated Phase 2 data due out October 19-23 and Phase 3 data due out in the Fourth Quarter. Also, could get a press release on news of their completed Phase 3 trial.
Buy Zone: $2.55 to $2.75
Profit Zone: $2.95 or higher
Stop Zone: $2.50 or below
Catabasis (CATB)
Catalyst Dates: Data update due out October 2 – 6th
Buy Zone: $.65 to $.75
Profit Zone: $.90 or higher
Stop Zone: $.60 or below
Soligenix (SNGX)
Catalyst Dates: Phase 3 interim analysis due out in October 2018.
Buy Zone: $1.35 to $1.55
Profit Zone: $1.80 or higher
Stop Zone: $1.15 or below
[Ed.note: Kyle Dennis runs BiotechBreakouts.com. He is an event-based trader, who prefers low-priced and small-cap biotech stocks.